Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.

CEO

Employees

Country

United States

ISIN

US92829J1043

Listings

0 Comments

Share your thoughts

FAQ

What is Virios Therapeutics stock price today?▼

The current price of VIRI is $0.16 USD — it has decreased by -95.5% in the past 24 hours. Watch Virios Therapeutics stock price performance more closely on the chart.

What is Virios Therapeutics stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Virios Therapeutics stocks are traded under the ticker VIRI.

What is Virios Therapeutics revenue for the last year?▼

Virios Therapeutics revenue for the last year amounts to 0 USD.

What is Virios Therapeutics net income for the last year?▼

VIRI net income for the last year is -6.4M USD.

How many employees does Virios Therapeutics have?▼

As of September 04, 2026, the company has 4 employees.

In which sector is Virios Therapeutics located?▼

Virios Therapeutics operates in the Technology sector.

When did Virios Therapeutics complete a stock split?▼

Virios Therapeutics has not had any recent stock splits.